NCT04974723View on ClinicalTrials.gov

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

CompletedOBSERVATIONAL
Enrollment

22,054

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Osteoporosis, Postmenopausal
Interventions
DRUG

Abaloparatide

Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)

DRUG

Teriparatide

Teriparatide subcutaneous (TPTD; Forteo®)

Trial Locations (1)

02210

Radius Health, Boston

Sponsors

Collaborators (1)

PRA Health Sciences
All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

Radius Health, Inc.

INDUSTRY